BioLineRx Ltd. (NASDAQ:BLRX – Free Report) – Stock analysts at Zacks Research issued their Q2 2026 earnings estimates for BioLineRx in a report issued on Thursday, May 28th. Zacks Research analyst J. Vandermosten anticipates that the biotechnology company will post earnings per share of $0.00 for the quarter. Zacks Research also issued estimates for BioLineRx’s Q3 2026 earnings at $0.00 EPS, Q4 2026 earnings at $0.00 EPS, FY2026 earnings at $0.00 EPS and FY2028 earnings at $0.00 EPS.
BioLineRx (NASDAQ:BLRX – Get Free Report) last posted its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.68. The company had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.34 million. BioLineRx had a negative net margin of 563.70% and a negative return on equity of 37.73%.
Read Our Latest Report on BLRX
BioLineRx Stock Performance
Shares of BLRX opened at $3.39 on Wednesday. The firm has a market capitalization of $14.81 million, a P/E ratio of -1.77 and a beta of 1.53. BioLineRx has a 52 week low of $2.15 and a 52 week high of $6.59. The stock has a 50 day moving average price of $2.67 and a two-hundred day moving average price of $2.88. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.43 and a current ratio of 1.58.
About BioLineRx
BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.
Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.
See Also
- Five stocks we like better than BioLineRx
- Berkshire Builds a Moat Around Homebuilders
- Tomato Prices Are Spiking, and These 2 Food Stocks Could Feel the Squeeze
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
